

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 510 is amended as follows:

**PART 510—NEW ANIMAL DRUGS**

1. The authority citation for 21 CFR part 510 continues to read as follows:

**Authority:** Secs. 201, 301, 501, 502, 503, 512, 701, 721, of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e).

**§ 510.600 [Amended]**

2. Section 510.600 *Names, addresses, and drug labeler codes of sponsors of approved applications* is amended in the table in paragraph (c)(1) by removing the entry for "Anaquest, Inc., A Subsidiary of BOC Health Care, Inc." and by alphabetically adding a new entry for "Ohmeda Pharmaceutical Products Division Inc., Liberty Corner, NJ 07938-0804.....010019"; and in the table in paragraph (c)(2) in the entry for "010019" by removing the sponsor name "Anaquest, Inc., A Subsidiary of BOC Health Care, Inc." and by adding in its place "Ohmeda Pharmaceutical Products Division Inc."

Dated: June 9, 1994.  
 Robert C. Livingston,  
 Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.  
 [FR Doc. 94-14709 Filed 6-16-94; 8:45 am]  
 BILLING CODE 4160-01-F

**21 CFR Parts 510 and 522**

**Animal Drugs, Feeds, and Related Products; Change of Sponsor**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for a new animal drug application (NADA) from Boehringer Ingelheim Animal Health, Inc., to Phoenix Scientific, Inc.  
**EFFECTIVE DATE:** June 17, 1994.

**FOR FURTHER INFORMATION CONTACT:** Benjamin A. Puyot, Center for Veterinary Medicine (HFV-130), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-594-1646.

**SUPPLEMENTARY INFORMATION:** Boehringer Ingelheim Animal Health, Inc., 2621 North Belth Hwy., St. Joseph, MO 64506-2002, has informed FDA that it has transferred ownership of, and all

rights and interests in NADA 99-169 for Oxytocin Injection to Phoenix Scientific, Inc., 3915 South 48th St. Terrace, P.O. Box 6457, St. Joseph, MO, 64506-0457. Accordingly, the agency is amending the regulations in 21 CFR 510.600(c)(1) and (c)(2) and in 21 CFR 522.1680(b) to reflect the change of sponsor.

**List of Subjects**

**21 CFR Part 510**

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

**21 CFR Part 522**

Animal drugs.  
 Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510 and 522 are amended as follows:

**PART 510—NEW ANIMAL DRUGS**

1. The authority citation for 21 CFR part 510 continues to read as follows:

**Authority:** Secs. 201, 301, 501, 502, 503, 512, 701, 721 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e).

2. Section 510.600 is amended in the table in paragraph (c)(1) by alphabetically adding a new entry for "Phoenix Scientific, Inc." and in the table in paragraph (c)(2) by numerically adding a new entry for "059130" to read as follows:

**§ 510.600 Names, addresses, and drug labeler codes of sponsors of approved applications.**

* * * * *	
(c) * * *	
(1) * * *	
Firm name and address	Drug labeler code
Phoenix Scientific, Inc. 3915 South 48th St. Terrace, P.O. Box 6457, St. Joseph, MO 64506-0457	059130
(2) * * *	
Drug labeler code	Firm name and address
059130	Phoenix Scientific, Inc. 3915 South 48th St. Terrace, P.O. Box 6457, St. Joseph, MO 64506-0457

**PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS**

3. The authority citation for 21 CFR part 522 continues to read as follows:

**Authority:** Sec. 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b).

**§ 522.1680 [Amended]**

4. Section 522.1680 *Oxytocin injection* is amended in paragraph (b) by removing "000010" and "and 058639" and by adding "058639, and 059130" before the word "in".

Dated: June 9, 1994.  
 Robert C. Livingston,  
 Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.  
 [FR Doc. 94-14708 Filed 6-16-94; 8:45 am]  
 BILLING CODE 4160-01-F

**21 CFR Part 529**

**Certain Other Dosage Form New Animal Drugs; Gentamicin Sulfate Intrauterine Solution**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of an abbreviated new animal drug application (ANADA) filed by Fort Dodge Laboratories. The ANADA provides for the use of a generic gentamicin solution for control of bacterial infections of the uterus (metritis) of horses and as an aid in improving conception in mares with uterine infections caused by bacteria sensitive to gentamicin.

**EFFECTIVE DATE:** June 17, 1994.

**FOR FURTHER INFORMATION CONTACT:** Larry D. Rollins, Center for Veterinary Medicine (HFV-110), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-594-1612.

**SUPPLEMENTARY INFORMATION:** Fort Dodge Laboratories, Fort Dodge, IA 50501, is the sponsor of ANADA 200-102, which provides for the use of a generic gentamicin solution (100 milligrams/milliliter (mg/mL)) for control of bacterial infections of the uterus (metritis) in horses and as an aid in improving conception in mares with uterine infections caused by bacteria sensitive to gentamicin.

ANADA 200-102 for Fort Dodge Laboratories' gentamicin sulfate solution (100 mg/mL gentamicin) is as a generic copy of Schering's Gentocin Solution (100 mg/mL gentamicin) in